US FDA says Intercept's drug can cause liver injury in patients without scarring
FDA warnings can significantly affect drug sales and investor confidence, as seen in past cases where safety concerns led to revenue decline for similar biotech stocks.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
FDA warnings can significantly affect drug sales and investor confidence, as seen in past cases where safety concerns led to revenue decline for similar biotech stocks.
What happened, with direct paths to the underlying reporting
FDA warns Intercept's liver drug may cause organ injury in specific patients.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.